Enantiomerically Enriched Bupropion Dosage Forms

Axsome Therapeutics has developed novel dosage forms containing enantiomerically enriched or pure bupropion for improved therapeutic treatment of depression and related psychiatric conditions. This patent represents significant innovation in pharmaceutical formulation that could enhance the clinical efficacy and tolerability of a widely-used antidepressant.

The Problem

Bupropion is a widely prescribed antidepressant medication that works by inhibiting the reuptake of dopamine and norepinephrine in the central nervous system. Currently, bupropion is manufactured and administered as a racemic mixture – containing equal amounts of two enantiomers (left and right-handed molecular forms).

While the racemic form is therapeutically effective, research suggests that individual enantiomers may exhibit different pharmacological properties and side effect profiles. Some enantiomers may contribute more to therapeutic benefits while others may contribute to unwanted side effects. Developing enantiomerically enriched or pure formulations could potentially offer improved efficacy, better tolerability, reduced side effects, or lower required doses compared to the current racemic formulation.

What This Invention Does

Axsome Therapeutics has developed novel dosage forms containing enantiomerically enriched or pure bupropion enantiomers. These formulations optimize the enantiomeric composition to maximize therapeutic benefits while potentially minimizing adverse effects. The dosage forms represent a new approach to utilizing this well-known active ingredient through enantiomeric selectivity.

By focusing on specific enantiomers, the inventors have created formulations that may provide superior clinical outcomes for patients suffering from depression and related psychiatric conditions. This represents a sophisticated pharmaceutical development approach that improves upon established medications through enantiomeric refinement.

Key Features

Enantiomeric Purity. Compositions containing preferentially enriched or pure single enantiomers of bupropion.

Improved Efficacy. Enantiomerically selective formulations designed for enhanced therapeutic effect.

Reduced Side Effects. Potential for improved tolerability through enantiomeric selectivity.

Antidepressant Application. Compositions useful for treating depression and related psychiatric conditions.

Who Is Behind It?

Axsome Therapeutics, Inc. is a United States-based biopharmaceutical company focused on developing innovative treatments for psychiatric and neurological disorders. The company specializes in novel formulations and enantiomerically optimized compounds. The patent lists Herriot Tabuteau as the primary inventor, representing the company’s pharmaceutical development expertise.

Why It Matters

Enantiomeric selectivity in pharmaceutical development represents a sophisticated approach to improving established medications. Bupropion is widely used globally, and improvements in efficacy and tolerability could benefit millions of patients with depression. This innovation demonstrates how advanced pharmaceutical chemistry and formulation science can enhance existing therapeutic compounds.

The IPC classifications (A61K 31/135 for pharmaceutical compounds including bupropion, and A61P 25/24 for psychotropic agents) reflect the pharmaceutical and psychiatric treatment focus. This work contributes to the ongoing evolution of antidepressant therapy and personalized medicine approaches in psychiatry.

---

AU 2026201399 was published in the Australian Official Journal of Patents on 19 March 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.

Related Concepts

Enantiomers are mirror-image molecular forms of the same compound that can differ dramatically in biological activity. The practice of isolating the therapeutically superior form – a chiral switch – has yielded several blockbuster drugs, including escitalopram derived from the racemic citalopram.

Bupropion is an antidepressant that also inhibits dopamine and norepinephrine reuptake, distinguishing it from conventional SSRIs. Enantiomerically refined dosage forms aim to concentrate therapeutic activity while reducing the side-effect burden associated with the less-active mirror-image molecule.